leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics engages Stern IR to expand its investor relations program and broaden visibility within US capital markets

Dan Legault, CEO of Antibe commented: “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities"

Market trader
Stern IR is a premier investor relations firm that provides consulting services to entrepreneurial healthcare and biotechnology companies.

Antibe Therapeutics Inc. (CVE:ATE) (OTCQB:ATBPF) said it has engaged Stern Investor Relations, Inc. to expand the company’s investor relations program and support efforts to broaden visibility within the US capital markets.

In a statement, Dan Legault, CEO of Antibe commented: “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities.”

“We believe that our lead drug, otenaproxesul, has the potential to deliver non-addictive pain relief without the gastrointestinal ulceration and bleeding associated with anti-inflammatory painkillers. We look forward to working with Stern IR to bring our message to these US audiences,” he added.

READ: Antibe Therapeutics says it has a clear path to billion-dollar revenue from its lead drug ATB-346

Under the terms of the agreement, Stern IR will provide strategic advisory and comprehensive investor relations services for an initial six-month term, at a fee of US$17,500 per month. Subsequent to the initial term, the engagement will continue on a month-to-month basis and can be terminated by either party on 60 days prior notice. The agreement is subject to acceptance by the TSX Venture Exchange.

Stern IR is a premier investor relations firm that provides consulting services to entrepreneurial healthcare and biotechnology companies. Since its inception in 1998, Stern IR has worked with more than 200 biotechnology, specialty pharmaceuticals, devices, and healthcare services companies in all stages of development and across all therapeutic areas.

Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine.

Antibe’s lead drug, otenaproxesul (previously known as ATB-346), targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin.

Contact the author at jon.hopkins@proactiveinvestors.com

Quick facts: Antibe Therapeutics Inc

Price: 0.365 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $140.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 12/8/20

2 min read